MeiraGTx News and Activities

Presence

MeiraGTx develops genetic medicines for inherited and severe diseases. Its products and services include gene therapy candidates, viral vector development, and manufacturing support for patients, hospitals, and research partners.

MeiraGTx products and services overview:

Gene therapies
Viral vectors
Cell therapy
Drug development
Clinical research
Manufacturing services

Revenue: ~$39 million

Employees: 300

Headquarters: New York, United States (USA)

MeiraGTx is one of the...

MeiraGTx is a company listed under the stock ticker MGTX (US).

Executives

View the org chart displaying its 19 main executives

Most searched biographies at MeiraGTx

Popular executive movements at MeiraGTx

Stuart Naylor, who was Chief Development Officer and Director, is promoted to Chief Scientific Officer, Ophthalmology (posted on May 21 2026).
Penny Fleck has joined the company as Chief Development Officer (posted on May 21 2026).

Create your alert
to follow the executive moves at MeiraGTx.